Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair MJ, Hofman P, Janssens A, Johansson M, van Kempen L, Kern I, Lopez-Rios F, Lüchtenborg M, Machado JC, Mohorcic K, Paz-Ares L, Popat S, Ryška A, Taniere P, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: wolf j. Lancet Reg Health Eur. 2024 Mar 1;38:100838. doi: 10.1016/j.lanepe.2024.100838. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476742 Free PMC article. Review.
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis.
Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, Pelusi N, Hartmann N, Rieke DT, Stephan-Falkenau S, Schuler M, Wermke M, Weichert W, Klauschen F, Haller F, Hummel HD, Sebastian M, Gattenlöhner S, Bokemeyer C, Esposito I, Jakobs F, von Kalle C, Büttner R, Wolf J, Hoffmann W. Kästner A, et al. Among authors: wolf j. Lancet Reg Health Eur. 2023 Nov 22;36:100788. doi: 10.1016/j.lanepe.2023.100788. eCollection 2024 Jan. Lancet Reg Health Eur. 2023. PMID: 38034041 Free PMC article.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: wolf j. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair M, Hofman P, Janssens A, van Kempen L, Kern I, Machado JC, Mohorčič K, Popat S, Ryška A, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: wolf j. Lancet Reg Health Eur. 2024 Mar 1;38:100839. doi: 10.1016/j.lanepe.2024.100839. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476751 Free PMC article. Review.
[Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version].
Schütte W, Gütz S, Nehls W, Blum TG, Brückl W, Buttmann-Schweiger N, Büttner R, Christopoulos P, Delis S, Deppermann KM, Dickgreber N, Eberhardt W, Eggeling S, Fleckenstein J, Flentje M, Frost N, Griesinger F, Grohé C, Gröschel A, Guckenberger M, Hecker E, Hoffmann H, Huber RM, Junker K, Kauczor HU, Kollmeier J, Kraywinkel K, Krüger M, Kugler C, Möller M, Nestle U, Passlick B, Pfannschmidt J, Reck M, Reinmuth N, Rübe C, Scheubel R, Schumann C, Sebastian M, Serke M, Stoelben E, Stuschke M, Thomas M, Tufman A, Vordermark D, Waller C, Wolf J, Wolf M, Wormanns D. Schütte W, et al. Among authors: wolf m, wolf j. Pneumologie. 2023 Oct;77(10):671-813. doi: 10.1055/a-2029-0134. Epub 2023 Oct 26. Pneumologie. 2023. PMID: 37884003 Free article. German.
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
Schuler M, Hense J, Darwiche K, Michels S, Hautzel H, Kobe C, Lueong S, Metzenmacher M, Herold T, Zaun G, Laue K, Drzezga A, Theegarten D, Nensa F, Wolf J, Herrmann K, Wiesweg M. Schuler M, et al. Among authors: wolf j. J Nucl Med. 2024 Jun 3;65(6):851-855. doi: 10.2967/jnumed.123.266979. J Nucl Med. 2024. PMID: 38575188 Clinical Trial.
A genomics-based classification of human lung tumors.
Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). Clinical Lung Cancer Genome Project (CLCGP), et al. Sci Transl Med. 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802. Sci Transl Med. 2013. PMID: 24174329 Free PMC article.
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J, Kemper M, Reinmuth N, Röper J, Janning M, Sommer L, Aguinarte L, Koch M, Wiesweg M, Wesseler C, Waller CF, Kauffmann-Guerrero D, Stenzinger A, Stephan-Falkenau S, Trautmann M, Lassmann S, Tiemann M, Klauschen F, Sebastian M, Griesinger F, Wolf J, Loges S, Frost N; National Network Genomic Medicine Lung Cancer (nNGM) Collaborator Group. Bischoff P, et al. Among authors: wolf j. J Thorac Oncol. 2024 May;19(5):803-817. doi: 10.1016/j.jtho.2023.12.015. Epub 2023 Dec 13. J Thorac Oncol. 2024. PMID: 38096950 Free article.
4,497 results